NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patients

Table 1 Clinical characteristics of patients with inflammatory bowel diseases

	CD (n = 810)	UC (n = 428)
Male/female (n)	434/376	202/226
Age (yr)	37.1 ± 12.6	43.7 ± 15.0
Age at presentation (yr)1	26.5 ± 10.6	31.3 ± 13.4
Duration (yr)1	10.7 ± 8.4	12.6 ± 9.9
Familial IBD1	11.8%	7.6%
Location in CD1
L1	28.2%
L2	18.9%	-
L3	51.2%
L4 only	1.7%
All L4	7.9%
Maximum extent in UC1
Proctitis	-	7.8%
Left-sided		52.3%
Extensive		39.9%
Behavior in CD1
B1	34.9%
B2	34.5%	-
B3	30.7%
Perianal disease1	41.2%	-
Frequent relapse in CD/chronic continuous in UC1	39.9%	27.6%
Arthritis1	38.6%	27.1%
Cutaneous1	7.8%	5.9%
Occular1	7.7%	3.8%
PSC1	2.4%	3.8%
Steroid use/refractory1	81.1%/11.6%	66.2%/12.3%
Azathioprine use1	68.3%	29.3%
Anti-TNF use1	33.2%	10.4%
Surgery in CD/colectomy in UC1	50.9%	10.0%
Smoking habits2
No	55.1%	71.6%
Yes	31.3%	12.4%
Previous	13.6%	16.0%

¹Clinical phenotype available in 789 Crohn's disease (CD) and 422 ulcerative colitis (UC) patients;

²Available in 691 CD and 388 UC patients. L1: Ileal; L2: Colon; L3: Ileocolonic; L4: Upper gastrointestinal; B1: Inflammatory; B2: Stenosing; B3: Penetrating. IBD: Inflammatory bowel disease; TNF: Tumor necrosis factor.